Latest UCB Stories
BRUSSELS, April 14, 2011 /PRNewswire/ -- New 5-year data from the longest prospective open-label Restless Legs Syndrome (RLS) study to date, show that NeuproÂ® (rotigotine) demonstrated continued symptomatic clinical benefit with a low risk of augmentation.
BRUSSELS, April 13, 2011 /PRNewswire/ -- New rotigotine data shown in four poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Hawaii, U.S., highlighted the importance in Parkinson's disease (PD) of addressing both motor- and non-motor symptoms, such as sleep.
BRUSSELS and INCLINE VILLAGE, Nev., Feb. 8, 2011 /PRNewswire/ -- UCB SA (Euronext Brussels: UCB), on behalf of its affiliate UCB Pharma S.A. (UCB), and PDL BioPharma, Inc.
ATLANTA, Dec. 6, 2010 /PRNewswire/ -- UCB today announced new findings for VimpatÂ® (lacosamide) C-V that offer additional support regarding the long-term benefits of the antiepileptic drug (AED) as an adjunctive therapy for adults with uncontrolled partial-onset seizures.
ATLANTA, Nov. 30, 2010 /PRNewswire/ -- New data on UCB's anti-epileptic drug (AED) VimpatÂ® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7.
ATLANTA, Nov. 22, 2010 /PRNewswire/ -- New stories and insights from the epilepsy community have been unveiled on EpilepsyAdvocate.com, including new interviews on "Women Succeeding with Epilepsy" and Epilepsy Advocate Radio.
ATLANTA, Nov. 18, 2010 /PRNewswire/ -- UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Rheumatoid Arthritis Family Scholarship Program for outstanding individuals affected by this condition.
ATLANTA, Nov. 9, 2010 /PRNewswire/ -- Today, UCB, Inc. celebrates the academic success of the 2010 UCB Family Epilepsy Scholarship recipients.
ATLANTA, Nov. 9, 2010 /PRNewswire/ -- UCB (EURONEXT: UCB) and U.S. based partner Immunomedics Inc.